Drug intelligence / Profile preview

GPS Plus

Development stage: Preclinical
Lead developer: SELLAS Life Sciences Group
Modality: Peptides

Overview

GPS Plus is a next-generation cancer immunotherapy developed by SELLAS Life Sciences. It is a peptide immunotherapy that targets the Wilms Tumor 1 (WT1) protein, which is overexpressed in various cancer types. SELLAS Life Sciences has granted 3D Medicines an exclusive license to develop, manufacture, and commercialize GPS Plus in Greater China.

Targets

WT1 (Wilms tumor protein)

Beyond the preview

Go deeper on GPS Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GPS Plus.

Explore the full profile